1/1

Export Ready

MYTERA 250 MG (ABIRATERONE ACETATE TABLETS)

Name: MYTERA 250 MG (ABIRATERONE ACETATE TABLETS)
SKU: 8416382
Price: 46.48 USD
Availability: InStock

Sold by Trigen Enterprises · Distributor, Exporter, Importer, Wholesaler · Mumbai, Maharashtra, India

Price

₹ 46.48 /Centimetre

In stock

MRP ~~₹ 203.93~~

Inclusive of all taxes

You Save: ₹ 157.45

Minimum order: 1 Centimetre

Export Snapshot

MOQ

1 Centimetre

Lead time

On request

Packaging

Standard export packaging

Shelf life / longevity

As per product specification

HSN Code

30049049

Origin

India

Port of dispatch

On request

Export markets served

Global markets

Values shown are for Trigen Enterprises.

Suitable for

Importers · Distributors · Wholesalers

Mumbai Dispatch on request Verified seller

Trigen Enterprises

Distributor, Exporter, Importer, Wholesaler · Mumbai, Maharashtra, India

Trigen Enterprises is a reputable pharmaceutical distributor based in Mumbai, operating since 2014. As authorized distributors and stockists for leading pharmaceutical companies such as Reliance Life Science, Mylan, Biocon, and Hetero Trigen Enterprises specializes in the oncology segment, offering high-quality products to healthcare providers. The company also engages in government tenders, including IHNS Ashvini, ensuring the availability of essential medications across sectors

Registered address: Mumbai, India. Industry: Healthcare, Medical Supplies & Pharmaceuticals > Drugs & Pharmaceuticals.

View profile All products

Established

2014

Employees

1–10

GST

27AJVPG8610J1ZQ

IEC code

Not shared

Export markets

Global markets

GlobalLinker Member Since

Oct 2024

Turnover

$1 MM - $2 MM

Incorporation Type

On request

Certifications & Awards

Product details

What are the specifications of this product?

Overview

MYTERA 250 MG (Abiraterone Acetate Tablets) is a prescription pharmaceutical product specifically formulated for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Each tablet contains 250 mg of Abiraterone Acetate, a potent selective inhibitor of CYP17 enzyme, instrumental in androgen production inhibition. By targeting androgen biosynthesis, MYTERA effectively decreases levels of testosterone and other androgens that promote prostate cancer cell growth. MYTERA 250 MG is typically prescribed in combination with a corticosteroid like prednisone to counteract potential side effects related to mineralocorticoid excess. These tablets are intended strictly for adult male patients under oncologist supervision, ensuring precision dosage and monitoring due to its critical therapeutic application. The formulation undergoes rigorous quality control to meet pharmaceutical standards, supporting efficacy in slowing disease progression and improving patient outcomes in advanced prostate cancer.

Product Description

Description provided by Trigen Enterprises.

Specifications

Dosage Strength	250 mg
Formulation Type	Film-coated tablet
Pharmacological Class	Androgen biosynthesis inhibitor
Therapeutic Area	Oncology - Prostate Cancer
Administration Route	Oral
Shelf Life	Typically 24 months from manufacture
Packaging Size	Available in packs of 30 tablets
Storage Temperature	15°C to 30°C
Regulatory Category	Prescription Medication

Use cases

Category	Pharmaceuticals > Oncology Drugs > Prostate Cancer Medication
Primary application	Wholesale, distribution, and international sourcing
Brand	Not specified
Product type	Product

Logistics & handling

Lead time	On request
Packaging	As per buyer requirement
Storage condition	As recommended by supplier
Origin	India
Form	As listed by supplier

Commercials (this seller)

Minimum order	1 Centimetre
Lead time	On request
Payment terms	As per negotiated commercial agreement.

Buyer questions

Frequently asked by buyers

Common questions B2B buyers ask before sourcing MYTERA 250 MG (ABIRATERONE ACETATE TABLETS). Answers compiled from verified sellers' commercial terms and platform data.

Q: Is MYTERA 250 MG suitable for early-stage prostate cancer?

A: MYTERA 250 MG is specifically approved for metastatic castration-resistant prostate cancer and is not indicated for early-stage prostate cancer treatment.

Q: Can MYTERA 250 MG be administered without corticosteroids?

A: No, MYTERA 250 MG treatment requires concurrent administration of corticosteroids like prednisone to manage side effects related to mineralocorticoid excess.

Q: What are the storage guidelines for MYTERA 250 MG tablets?

A: Store MYTERA 250 MG tablets at temperatures between 15°C and 30°C, in a dry place away from direct sunlight and moisture to maintain drug stability.

Q: Are there any specific patient monitoring requirements while using MYTERA 250 MG?

A: Yes, patients should be regularly monitored for liver function, blood pressure, and potassium levels due to potential adverse effects associated with Abiraterone therapy.

Q: How does MYTERA 250 MG inhibit prostate cancer progression?

A: MYTERA 250 MG inhibits the CYP17 enzyme critical in androgen biosynthesis, thus reducing testosterone levels that fuel prostate cancer cell growth.

Question not answered? Ask sellers directly — typical response within 4 hours.